Piotr Rutkowski

Summary

Affiliation: Institute of Oncology
Country: Poland

Publications

  1. ncbi request reprint Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation
    Piotr Rutkowski
    Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue Bone Sarcoma and Melanoma, Roentgena 5, 02 781 Warsaw, Poland 48 22 6439375 48 22 6439791
    Expert Opin Drug Saf 13:1249-58. 2014
  2. pmc Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Sarcoma 2011:959132. 2011
  3. pmc What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781, Warsaw, Poland
    Med Oncol 30:765. 2013
  4. pmc Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Oncologist 18:689-96. 2013
  5. pmc Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02 781, Warsaw, Poland
    Mol Diagn Ther 17:9-19. 2013
  6. pmc Surgery quality and tumor status impact on survival and local control of resectable liposarcomas of extremities or the trunk wall
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Clin Orthop Relat Res 471:860-70. 2013
  7. pmc The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center, Warsaw, Poland
    BMC Cancer 12:107. 2012
  8. ncbi request reprint Emergency surgery in the era of molecular treatment of solid tumours
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
    Lancet Oncol 10:157-63. 2009
  9. doi request reprint Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Melanoma Res 18:246-52. 2008
  10. ncbi request reprint Developments in targeted therapy of advanced gastrointestinal stromal tumors
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Recent Pat Anticancer Drug Discov 3:88-99. 2008

Detail Information

Publications56

  1. ncbi request reprint Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation
    Piotr Rutkowski
    Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue Bone Sarcoma and Melanoma, Roentgena 5, 02 781 Warsaw, Poland 48 22 6439375 48 22 6439791
    Expert Opin Drug Saf 13:1249-58. 2014
    ..Dabrafenib is the second approved selective BRAF inhibitor (after vemurafenib) for the treatment of unresectable or metastatic BRAF V600-positive melanoma...
  2. pmc Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Sarcoma 2011:959132. 2011
    ..Following partial response on imatinib significant percentage of patients may be rendered free of the disease by surgery of the residual tumor...
  3. pmc What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781, Warsaw, Poland
    Med Oncol 30:765. 2013
    ..After introduction of subsequent lines of therapy (as sunitinib), the effect of primary mutational status on the long-term OS is also less visible...
  4. pmc Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Oncologist 18:689-96. 2013
    ....
  5. pmc Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02 781, Warsaw, Poland
    Mol Diagn Ther 17:9-19. 2013
    ..This article discusses patient selection criteria for extended adjuvant therapy with imatinib, different classifications of risk of recurrence, and assessment of the response to therapy...
  6. pmc Surgery quality and tumor status impact on survival and local control of resectable liposarcomas of extremities or the trunk wall
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Clin Orthop Relat Res 471:860-70. 2013
    ..However, it is unclear which other factors, including the initial surgery quality and recurrent tumors, influence survival in localized liposarcomas (LPS)...
  7. pmc The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center, Warsaw, Poland
    BMC Cancer 12:107. 2012
    ..The aim of the study was to analyze the outcomes and factors predicting results of SU therapy in inoperable/metastatic CD117(+) GIST patients after IM failure...
  8. ncbi request reprint Emergency surgery in the era of molecular treatment of solid tumours
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
    Lancet Oncol 10:157-63. 2009
    ..Special attention is given to advanced gastrointestinal stromal tumours and colorectal cancer, and therapy with imatinib, sunitinib, and bevacizumab...
  9. doi request reprint Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Melanoma Res 18:246-52. 2008
    ..The LY MM RT-PCR seems to be an effective prognostic tool for stage III melanoma patients. The MM RT-PCR analysis of single peripheral blood sample in these patients did not have additional prognostic value...
  10. ncbi request reprint Developments in targeted therapy of advanced gastrointestinal stromal tumors
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Recent Pat Anticancer Drug Discov 3:88-99. 2008
    ..This review focuses on the current achievements in targeted therapy of advanced GISTs, and how the insight into the resistance mechanisms may allow in the near future to treat patients with advanced GISTs...
  11. doi request reprint Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes
    P Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Eur J Surg Oncol 37:890-6. 2011
    ..Approval of imatinib for adjuvant treatment of gastrointestinal stromal tumours (GIST) raised discussion about accuracy of prognostic factors in GIST and the clinical significance of the available risk stratification criteria...
  12. ncbi request reprint Gastrointestinal stromal tumors: key to diagnosis and choice of therapy
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Mol Diagn Ther 12:131-43. 2008
    ..This article discusses the histologic and molecular criteria for distinguishing GISTs from other types of sarcoma, and the molecular diagnostic tools that are currently available or in development to assist in therapy decisions...
  13. pmc Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials
    Piotr Rutkowski
    Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    J Clin Oncol 28:1772-9. 2010
    ..Dermatofibrosarcoma protuberans (DFSP) is a dermal sarcoma typically carrying a translocation between chromosomes 17 and 22 that generates functional platelet-derived growth factor B (PDGFB)...
  14. doi request reprint Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection
    P Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
    J Eur Acad Dermatol Venereol 25:264-70. 2011
    ..Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma of the skin characterized by the presence of specific COL1A1-PDGFB fusion protein, which appears as a consequence of the t(17;22) (q22;q13) translocation...
  15. pmc Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Ann Surg Oncol 17:3314-23. 2010
    ....
  16. ncbi request reprint Cutaneous melanoma with nodal metastases in elderly people
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Dermatol 49:907-13. 2010
    ..The impact of age on melanoma patient outcomes is uncertain...
  17. doi request reprint Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Cancer 117:4916-24. 2011
    ....
  18. ncbi request reprint The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST)
    P Rutkowski
    Department of Soft Tissue Bone Sarcoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, 02 781 Warsaw, Poland
    Neoplasma 50:438-42. 2003
    ..Surgery in combination with adjuvant imatinib treatment may result in improved survival with patients with advanced GIST...
  19. doi request reprint Melanoma without a detectable primary site with metastases to lymph nodes
    Piotr Rutkowski
    Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Dermatol Surg 36:868-76. 2010
    ..To compare outcomes of patients with clinical nodal melanoma metastases that occurred without a detectable primary tumor (melanoma of unknown primary site; MUP) with those with a known primary site (KPM)...
  20. ncbi request reprint Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Med Sci Monit 13:CR515-522. 2007
    ....
  21. ncbi request reprint Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    J Surg Oncol 93:304-11. 2006
    ..The aim of the study was to analyze the surgical possibilities of unresectable and/or metastatic GIST CD117(+) patients during imatinib treatment...
  22. ncbi request reprint Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcomas, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 100:463-71. 2002
    ..Serum assays of IL-6, IL-8 and TNF RII before or after the treatment may be useful in establishing soft tissue sarcoma patients prognosis...
  23. ncbi request reprint Lymph node status and survival in cutaneous malignant melanoma--sentinel lymph node biopsy impact
    P Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, W Roentgena Str 5, 02 781, Warsaw, Poland
    Eur J Surg Oncol 29:611-8. 2003
    ....
  24. ncbi request reprint In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection
    P Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena Strasse 5, 02 781 Warsaw, Poland
    Eur J Cancer 42:159-64. 2006
    ..8%; P<0.0001). IT/LR incidence in the entire group of SLN+/-CLND patients was similar to that observed in TLND patients and it was affected by presence of nodal metastases, Breslow thickness and lower extremity location...
  25. ncbi request reprint Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781, Warsaw, Poland
    Ann Surg Oncol 14:2018-27. 2007
    ..The introduction of adjuvant imatinib in gastrointestinal stromal tumors (GISTs) raised debate over the accuracy of National Institutes of Health risk criteria and the significance of other prognostic factors in GIST...
  26. ncbi request reprint Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center, Institute of Oncology, Warsaw, Poland
    J Cancer Res Clin Oncol 133:589-97. 2007
    ..To analyze the outcomes of treatment and factors predicting effects of imatinib (IM) therapy in inoperable/metastatic gastrointestinal stromal tumors (GIST) CD117(+) patients...
  27. ncbi request reprint Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay
    Ruka Włodzimierz
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, W Roentgena Str 5, 02 781 Warsaw, Poland
    Ann Surg Oncol 11:988-97. 2004
    ....
  28. ncbi request reprint The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone
    Wlodzimierz Ruka
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center, Institute of Oncology, Warsaw, Poland
    Int J Radiat Oncol Biol Phys 78:494-8. 2010
    ..To assess the outcomes of radiotherapy, in terms of local control and treatment complications, of advanced or difficult giant cell tumors of bone (GCTB) that could not be treated by surgery...
  29. ncbi request reprint Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma
    Zbigniew I Nowecki
    Department of Soft Tissue Bone Sarcoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena Str 5, 02 781, Warsaw, Poland
    Ann Surg Oncol 13:1655-63. 2006
    ..SLN biopsy failure rate was defined as nodal recurrence in the biopsied regional basin without previous local or in-transit recurrence...
  30. doi request reprint Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcoma and Melanoma, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Ann Surg Oncol 20:2937-43. 2013
    ..Preoperative imatinib therapy of locally advanced GIST may facilitate resection and decrease morbidity of the procedure...
  31. ncbi request reprint Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience
    Zbigniew I Nowecki
    Department of Soft Tissue Bone Sarcoma, M Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
    Melanoma Res 13:35-43. 2003
    ..SLN status is the most important factor proven to distinguish high and low risk melanoma patients...
  32. pmc Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression
    Jerzy Ostrowski
    Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Warsaw, Poland
    BMC Cancer 9:413. 2009
    ..To clarify the molecular characteristics of differentially expressed genes according to GIST receptor mutations, we combined microarray-based analysis with detailed functional annotations...
  33. doi request reprint The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3)
    Zbigniew I Nowecki
    Department of Soft Tissue, Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Ann Surg Oncol 15:2223-34. 2008
    ....
  34. ncbi request reprint Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features
    Joanna Przybyl
    Department of Molecular and Translational Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland
    Int J Biochem Cell Biol 53:505-13. 2014
    ..Over half of SynSa patients develop metastasis or local recurrence, but the underlying molecular mechanisms of the aggressive clinical behavior remain poorly characterized...
  35. ncbi request reprint Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas
    Wirginiusz Dziewirski
    Department of Soft Tissue Bone Sarcoma, M Sklodowska Curie Cancer Center and Institute of Oncology, W K Roentgena Str 5, Warsaw, 02 781, Poland
    Ann Surg Oncol 13:245-52. 2006
    ..The purpose of this study was to analyze the results of treatment of retroperitoneal soft tissue sarcomas (RSTS) by surgery combined with intraoperative brachytherapy (IOBRT)...
  36. ncbi request reprint [The prognostic role of clinical factors, VEGF, IL-8 and sTNF-R1 in cutaneous melanomas at locoregional stage]
    Iwona Ługowska
    Maria Sklodowska Curie Cancer Centre Institute of Oncology in Warsaw, Poland, Department of Soft Tissue Bone Sarcoma and Melanoma
    Pol Merkur Lekarski 32:22-7. 2012
    ..The aim of the study was to assess the prognostic value of clinical factors and serum cytokines of patients with cutaneous melanoma in locoregional stage...
  37. ncbi request reprint Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcomas, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    J Surg Oncol 84:151-9. 2003
    ....
  38. doi request reprint Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial
    Alexander M M Eggermont
    Alexander M M Eggermont, Institut de Cancerologie Gustave Roussy, Villejuif, Paris Sud, and Université Paris Sud, Kremlin Bicetre, Paris, France Stefan Suciu, Larissa Polders, and Michel Praet, European Organisation for Research and Treatment of Cancer, Brussels, Belgium Piotr Rutkowski, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland Jeremy Marsden, University Hospital Birmingham, Birmingham Philippa Corrie, Addenbrookes Hospital, Cambridge Poulam M Patel, University of Nottingham, Nottingham Neville Davidson, Broomfield Hospital, Broomfield, United Kingdom Mario Santinami, Istituto Nazionale dei Tumori, Milan Paolo A Ascierto, Istituto Nazionale Tumori Fondazione Pascale, Napoli Lorenzo Borgognoni, Istituto Tumori Toscano, S Maria Annunziata Hospital, Florence Maria Grazia Bernengo, University Hospital Turin, Turin, Italy Steinar Aamdal, Oslo University Hospital and Radium Hospital, Oslo
    J Clin Oncol 31:3831-7. 2013
    ..The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) and IgG antibody responses. The EORTC 18961 trial compared the efficacy of GM2-KLH/QS-21 vaccination versus observation...
  39. pmc Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases
    Joanna Przybyl
    Department of Molecular Biology, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, 5 WK Roentgen Street, 02 781 Warsaw, Poland
    Tumour Biol 33:2245-53. 2012
    ..Furthermore, we describe the first case of a complex rearrangement possibly linking SS to REPS2 gene...
  40. ncbi request reprint Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients
    Dorota Rataj
    Department of Soft Tissue and Bone Cancer, Institute of Oncology, Warsaw, Poland
    Cancer Nurs 28:172-8. 2005
    ..A number of steps can be taken to minimize the morbidity associated with IFN-alpha-2b therapy, resulting in an improvement in both QOL and patient compliance...
  41. ncbi request reprint Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland
    Jan Steffen
    Department of Immunology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 111:67-71. 2004
    ..Larger studies are needed to evaluate the impact of the high frequency of germline NBS1 mutations on the cancer burden in the Slav populations...
  42. doi request reprint Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level
    Z I Nowecki
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Roentgena Str 5, 02 781 Warsaw, Poland
    Br J Dermatol 159:597-605. 2008
    ..There is a need for biomarkers to identify patients at risk for disease progression after resection of melanoma regional lymph node metastasis...
  43. ncbi request reprint Oncogenic osteomalacia associated with phosphaturic mesenchymal tumour, mixed connective tissue type of the knee
    Anna Szumera-Ciećkiewicz
    Department of Pathology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, ul Roentgena 5, 02 781 Warszawa
    Pol J Pathol 60:193-8. 2009
    ..Intra-articular PMTMCT of the knee was diagnosed and surgically removed. We describe histopathological features of PMTMCT and review the most recent studies concerning this diagnostic problem...
  44. doi request reprint Diagnostic yield and safety of endoscopic ultrasound-guided trucut [corrected] biopsy in patients with gastric submucosal tumors: a prospective study
    M Polkowski
    Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Warsaw, Poland
    Endoscopy 41:329-34. 2009
    ..Endoscopic-ultrasound-guided trucut needle biopsy (EUS-TCB) has not been adequately evaluated in patients with submucosal tumors (SMTs)...
  45. ncbi request reprint Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications
    Joanna Przybyl
    Department of Molecular and Translational Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, 5 W K Roentgen Street, 02 781, Warsaw, Poland
    Med Oncol 31:109. 2014
    ..Moreover, we demonstrate the prognostic value of molecular PB testing at the time of routine histopathological diagnosis. ..
  46. pmc Small bowel tumors detected and missed during capsule endoscopy: single center experience
    Edyta S Zagorowicz
    Edyta S Zagorowicz, Anna M Pietrzak, Ewa Wronska, Jacek Pachlewski, Ewa Kraszewska, Jaroslaw Regula, Department of Gastroenterology, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, 02 781 Warsaw, Poland
    World J Gastroenterol 19:9043-8. 2013
    ..To characterize small bowel (SB) tumors detected by capsule endoscopy (CE), and identify missed tumors...
  47. pmc Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy
    Joanna Przybyl
    Department of Molecular Biology, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, 02 781 Warsaw, Poland
    Sarcoma 2012:249219. 2012
    ..Additional research efforts are required to fully explore the protein-protein interactions of SS18-SSX oncoproteins and the pathways that are regulated by these partnerships for the development of effective targeted therapy...
  48. doi request reprint Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib
    W Ruka
    Department of Soft Tissue Bone Sarcoma and Melanoma, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Eur J Surg Oncol 35:87-91. 2009
    ..We explored this possibility in the course of treating patients as part of a treatment-use trial, the objective of which was to provide access to sunitinib treatment...
  49. ncbi request reprint Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay
    J Kulik
    Department of Molecular Biology, Cancer Center-Institute, Warsaw, Poland
    Melanoma Res 11:65-73. 2001
    ..Therefore we do not recommend the use of MUC-18 as a standard value marker...
  50. ncbi request reprint Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors
    Jerzy Lasota
    Department of Soft Tissue Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Lab Invest 87:1029-41. 2007
    ..4 months. Based on these findings, we conclude that presence of homozygous KIT exon 11 mutations is associated with malignant course of disease and should be considered an adverse prognostic marker in GISTs...
  51. ncbi request reprint Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST)
    Włodzimierz Ruka
    Med Sci Monit 10:LE13-4. 2004
  52. ncbi request reprint Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma
    Jolanta Szenajch
    Department of Oncology, Military Institute of Medicine, Szaserow 128 Street, 00 909 Warsaw, Poland
    Clin Chem 49:1450-7. 2003
    ....
  53. doi request reprint Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii89-93. 2008
  54. doi request reprint Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii35-8. 2008
  55. ncbi request reprint [Cutaneous melanoma during pregnancy at the Cancer Center-Institute in Warsaw]
    Zbigniew I Nowecki
    Kliniki Nowotworów Tkanek Miekkich i Kości, Centrum Onkologii Instytut im M Skłodowskiej Curie w Warszawie
    Ginekol Pol 74:525-32. 2003
    ..The most important factor influencing prognosis of melanoma is the stage of the disease at the diagnosis. There are no grounds for abortion in pregnant women with melanoma in I/II/III stages...
  56. ncbi request reprint Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation
    Agnieszka Wozniak
    Department of General Medical Oncology, Catholic University of Leuven, Leuven, Belgium
    Int J Cancer 122:2160-4. 2008
    ..This observation confirms that imatinib can be successfully used in familial GISTs, as it is used in the sporadic advanced tumors, and that tumors bearing a KIT p.Q575_P577delinsH mutation are responsive to imatinib treatment...